Journey Medical Corporation DERM R2K
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 20.5% over 5 years.
CONS
- Revenue declined at -5.7% CAGR over 5 years.
- Trading 31.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DERM Journey Medical Corporation R2K | 6.31 | - | $173.74M | - | -13.43% | -36.62% | -5.66% | 20.47% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.45M | 10.72M | 15.29M | 19.61M | 20.80M | 18.23M | 16.04M | 12.16M | 16.96M | 15.28M | 13.03M | 14.86M | - | - | 13.14M | 15.01M | 17.63M | 16.08M | 15.96M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.79M | 4.94M | 5.75M | 5.44M | 6.22M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.35M | 10.07M | 11.88M | 10.64M | 9.74M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.67M | 12.95M | 13.40M | 11.08M | 11.23M |
| Operating Income | 239.00K | 585.00K | -13.76M | -12.65M | -888.00K | -7.14M | -9.49M | -9.56M | -7.65M | 17.25M | -10.09M | -2.93M | - | - | -3.32M | -2.88M | -1.53M | -443.00K | -1.49M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.10M | -1.71M | -292.00K | 774.00K | -189.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 891.00K | 937.00K | 937.00K | 933.00K | 892.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.07M | -3.74M | -2.31M | -1.25M | -2.23M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 60.00K | 0 | 0 | 0 |
| Net Income | 29.00K | 268.00K | -11.87M | -10.65M | -1.38M | -7.53M | -10.08M | -10.14M | -8.36M | 16.79M | -10.44M | -3.36M | - | - | -4.07M | -3.80M | -2.31M | -1.25M | -2.23M |
| Diluted EPS | 0.00 | 0.02 | -1.30 | -1.16 | -0.08 | -0.43 | -0.57 | -0.57 | -0.46 | 0.80 | -0.53 | -0.17 | -0.12 | - | -0.18 | -0.16 | -0.09 | - | -0.08 |
| R&D Expense | - | - | 29.00K | 718.00K | 1.27M | 2.61M | 2.81M | 2.03M | 1.77M | 2.23M | 7.88M | 913.00K | 842.00K | - | 39.00K | - | 287.00K | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 44.53M | - | 73.67M | 79.18M | 56.13M | 61.86M |
| Cost of Revenue | - | - | 30.77M | 22.89M | 20.88M | 20.92M |
| Gross Profit | - | - | 42.89M | 56.29M | 35.26M | 40.93M |
| Operating Expenses | - | - | 70.41M | 55.22M | 53.48M | 49.11M |
| Operating Income | 7.85M | - | -27.52M | 1.07M | -18.23M | -8.17M |
| EBITDA | - | - | -23.18M | 1.92M | -8.40M | -3.33M |
| Interest Expense | - | - | 2.02M | 1.70M | 2.70M | 3.70M |
| Pretax Income | - | - | -29.57M | -3.63M | -14.61M | -11.37M |
| Tax Provision | - | - | 63.00K | 221.00K | 61.00K | 60.00K |
| Net Income | 5.28M | - | -29.63M | -3.85M | -14.67M | -11.43M |
| Diluted EPS | 0.49 | -4.32 | -1.69 | -0.21 | -0.72 | - |
| R&D Expense | - | 2.74M | 10.94M | 7.54M | 9.86M | 480.00K |
Compounded Sales Growth
| 5 Years: | -5.66% |
| 1 Year: | 21.50% |
Compounded Profit Growth
| 5 Years: | 20.47% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -21.71% |
| 6 Months: | -19.72% |
| 3 Months: | -22.77% |
| 1 Month: | +26.20% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 51.91M | - | 105.16M | 76.85M | 80.24M | 94.59M |
| Current Assets | - | - | - | 77.68M | 56.45M | 48.18M | 66.87M |
| Cash & Equivalents | - | 8.25M | - | 32.00M | 27.44M | 20.30M | 24.09M |
| Inventory | - | - | - | 14.16M | 10.21M | 14.43M | 9.62M |
| Receivables | - | - | - | 28.21M | 15.22M | 10.23M | 29.78M |
| Total Liabilities | - | 41.61M | - | 88.18M | 56.50M | 60.17M | 62.74M |
| Current Liabilities | - | 28.06M | - | 66.83M | 41.87M | 35.17M | 37.44M |
| Long Term Debt | - | - | - | 19.83M | 14.62M | 24.88M | 25.28M |
| Total Debt | - | - | - | 22.96M | 14.73M | 25.08M | 25.40M |
| Total Equity | 2.75M | 10.29M | - | 16.98M | 20.35M | 20.07M | 31.85M |
| Shares Outstanding | - | - | - | 17.77M | 19.32M | 22.15M | 27.14M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.13M | - | -13.53M | 5.24M | -9.13M | -12.44M |
| Investing Cash Flow | -1.20M | - | -20.00M | -5.00M | -15.00M | 0 |
| Financing Cash Flow | -487.00K | - | 16.46M | -4.80M | 16.99M | 16.23M |
| Capital Expenditure | - | -10.00M | -20.00M | -5.00M | -15.00M | - |
| Free Cash Flow | - | - | -33.53M | 240.00K | -24.13M | -12.44M |
| Net Change in Cash | - | - | -17.08M | -4.56M | -7.13M | 3.79M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 58.2% | 71.1% | 62.8% | 66.2% |
| Operating Margin % | 17.6% | - | -37.4% | 1.4% | -32.5% | -13.2% |
| Net Margin % | 11.9% | - | -40.2% | -4.9% | -26.1% | -18.5% |
| ROE % | 51.3% | - | -174.5% | -18.9% | -73.1% | -35.9% |
| ROCE % | 32.9% | - | -71.8% | 3.1% | -40.5% | -14.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Wasatch Advisors LP | 9.91% | 2.13M | $13.46M |
| 2 | Tang Capital Management, LLC | 7.48% | 1.61M | $10.16M |
| 3 | Vanguard Capital Management LLC | 5.02% | 1.08M | $6.83M |
| 4 | Blackrock Inc. | 4.52% | 972.86K | $6.14M |
| 5 | Opaleye Management Inc. | 4.46% | 960.00K | $6.06M |
| 6 | J. Goldman & Co., L.P. | 2.32% | 500.19K | $3.16M |
| 7 | Pale Fire Capital SE | 2.24% | 481.99K | $3.04M |
| 8 | Geode Capital Management, LLC | 2.15% | 463.20K | $2.92M |
| 9 | UBS Group AG | 1.81% | 390.14K | $2.46M |
| 10 | Millennium Management Llc | 1.78% | 383.07K | $2.42M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DERM